felin
infecti
periton
fip
infect
result
clinic
sign
invari
fatal
despit
clinic
intervent
fip
immunemedi
diseas
treatment
mainli
aim
control
immun
respons
trigger
infect
felin
coronaviru
fcov
immun
suppress
drug
prednison
cyclophosphamid
may
slow
diseas
progress
produc
cure
nearli
everi
publish
case
report
attempt
therapi
clinic
fip
glucocorticoid
use
howev
control
studi
evalu
effect
glucocorticoid
therapi
fip
veterinarian
prescrib
immun
modul
treat
cat
fip
document
control
evid
efficaci
suggest
agent
may
benefit
infect
anim
restor
compromis
immun
function
therebi
allow
patient
control
viral
burden
recov
clinic
sign
howev
nonspecif
stimul
immun
system
may
contraind
clinic
sign
develop
progress
result
immunemedi
respons
mutat
fcov
oldest
report
publish
disqu
et
al
treat
cat
suspect
felin
infecti
periton
fip
prednisolon
penicillin
dihydrostreptomycin
cat
remain
alert
point
time
etiolog
fip
unknown
diagnosi
fip
confirm
disqu
et
al
addit
glucocorticoid
cytostat
drug
cyclophosphamid
use
suppress
immun
system
bilkei
use
combin
cyclophosphamin
mgkg
h
prednisolon
mgkg
h
ampicillin
mgkg
h
cat
suspect
fip
followedup
week
these
cat
cat
regard
healthi
therapi
cat
includ
studi
confirm
diagnosi
inclus
criteria
extrem
vagu
control
group
exist
bilkei
chang
et
al
treat
cat
glucocorticoid
antibiot
one
cat
receiv
cyclophosphamid
addit
cat
die
day
day
respect
fip
confirm
histopatholog
chang
et
al
watari
et
al
publish
case
report
includ
cat
month
year
old
treat
ozagrel
hydrochlorid
thromboxan
synthetas
inhibitor
mgkg
mgkg
h
respect
prednisolon
mgkg
h
ozagrel
hydrochlorid
suppress
platelet
aggreg
product
thromboxan
strong
platelet
aggreg
agent
hiraku
et
al
cat
receiv
lower
dose
clinic
healthi
week
initi
therapi
month
treatment
discontinu
cat
still
remain
healthi
next
month
cat
receiv
mgkg
good
clinic
wwwelseviercomlocatevetimm
avail
onlin
wwwsciencedirectcom
veterinari
immunolog
immunopatholog
condit
day
effus
also
vanish
stay
healthi
therapi
stop
month
occurr
nasal
bleed
ascit
recur
cat
die
month
initi
remiss
although
like
fip
confirm
case
watari
et
al
weiss
et
al
administ
antivir
drug
ribavirin
mgkg
h
day
oral
intramuscularli
intraven
specif
pathogenfre
spf
kitten
h
experiment
challeng
exposur
fipcaus
viru
ribavirin
nucleosid
analog
prevent
format
viral
protein
like
interf
mrna
process
kitten
includ
ribavirintr
untreat
kitten
succumb
fip
clinic
sign
diseas
even
sever
ribavirintr
kitten
mean
surviv
time
shorten
although
activ
felin
coronaviru
fcov
vitro
weiss
oostromram
barlough
scott
ribavirin
therefor
effect
treat
cat
fip
due
sever
side
effect
weiss
et
al
weiss
et
al
tri
decreas
toxic
ribavirin
incorpor
lecithincontain
liposom
give
lower
dosag
mgkg
intraven
cat
challeng
fipcaus
viru
howev
therapeut
concentr
drug
achiev
regim
weiss
et
al
madewel
et
al
treat
cat
melphalan
alkyl
agent
nitrogen
mustard
group
irrevers
interact
dna
cat
old
male
cat
felin
leukemia
virusposit
suspect
fip
cat
treat
melphalan
start
mgkg
everi
h
month
prednison
mgkg
everi
h
reduc
week
next
week
mgkg
everi
h
ampicillin
mgkg
everi
h
per
day
streptokinas
iucat
intraperiton
abdominocentes
everi
h
day
addit
vitamin
miner
administ
cat
respond
well
treatment
month
develop
myeloprolif
disord
die
diagnosi
fip
confirm
case
either
histopatholog
evid
fip
madewel
et
al
immunemodulatori
drug
wide
use
cat
fip
includ
tylosin
robison
colgrov
parker
robison
et
al
tylosin
belong
macrolid
antibiot
like
macrolid
also
immunemodulatori
effect
fraschini
et
al
ra
anderson
katahira
et
al
b
baba
et
al
robison
use
tylosin
mgkgday
cat
achiev
temporari
remiss
howev
fip
confirm
case
colgrov
parker
treat
natur
occur
case
suspect
fip
tylosin
start
mgkg
oral
h
prednisolon
start
mgkgday
well
support
treatment
fluid
vitamin
one
cat
die
day
other
still
healthi
day
day
respect
diagnosi
fip
howev
also
confirm
cat
colgrov
parker
robison
et
al
treat
one
cat
suspect
fip
tylosin
oral
mgcat
h
well
prednisolon
mgcat
tylosin
mgcat
intraperiton
abdominocenti
cat
recov
within
month
sever
cat
treat
similar
manner
howev
die
robison
et
al
report
ford
immun
modul
promodulin
use
cat
suspect
fip
respond
favor
treatment
rapid
remiss
clinic
sign
associ
fip
anorexia
fever
effus
seen
fip
also
confirm
control
group
longterm
follow
includ
studi
ford
bilkei
treat
cat
suspect
fip
group
week
receiv
either
ampicillin
mgkgday
prednisolon
mgkgday
cyclophoshamid
mgkgday
dexamethason
mgkg
day
day
ampicillin
mgkg
everi
h
day
human
interferona
iu
cat
day
week
week
paraimmun
induc
baypamun
mlcatweek
week
noth
cat
followedup
year
depend
group
cat
die
within
year
fip
confirm
cat
inclus
criteria
unclear
bilkei
weiss
et
al
perform
control
treatment
trial
use
human
interferona
propionibacterium
acn
immunemodulatori
compound
combin
placebo
human
interferona
direct
antivir
effect
induc
gener
antivir
state
interferonacontain
cell
protect
viru
replic
vitro
antivir
efficaci
human
interferona
fipcaus
fcov
strain
demonstr
weiss
oostromram
weiss
et
al
includ
specif
pathogenfre
cat
treat
control
induc
fip
experiment
neither
prophylact
therapeut
administr
high
dose
iukg
iukg
interferona
felin
interferonb
iukg
p
acn
mgcat
mgcat
significantli
reduc
mortal
treat
versu
untreat
cat
cat
treat
iukg
interferona
combin
p
acn
mean
surviv
time
significantli
prolong
day
one
studi
publish
diagnosi
fip
confirm
artifici
induct
fip
histopatholog
end
studi
control
group
includ
weiss
et
al
recent
felin
interferonv
licens
use
veterinari
medicin
european
countri
japan
interferon
speciesspecif
felin
interferon
differ
human
one
concern
antigen
therefor
caus
antibodi
develop
cat
antivir
efficaci
felin
cell
fcov
replic
inhibit
felin
interferonv
vitro
mochizuki
et
al
ishida
et
al
treat
cat
older
year
age
suspect
fip
felin
interferonv
iukg
subcutan
everi
h
initi
clinic
improv
subsequ
everi
day
glucocorticoid
support
care
ishida
et
al
cat
surviv
period
year
despit
initi
present
effus
diagnosi
surviv
cat
confirm
control
group
exist
studi
ishida
et
al
recent
perform
random
placebocontrol
doubleblind
treatment
trial
cat
fip
treat
interferonv
placebo
cat
fip
confirm
histolog
andor
immunohistochem
immunofluoresc
stain
fcov
antigen
effus
tissu
macrophag
cat
receiv
glucocorticoid
either
dexamethason
case
effus
mgkg
intrathorac
intraperiton
inject
everi
h
prednisolon
mgkg
oral
everi
h
addit
cat
receiv
either
placebo
interferonv
ukg
subcutan
everi
h
day
subsequ
everi
week
statist
signific
differ
mean
surviv
time
cat
treat
interferonv
versu
placebo
cat
surviv
period
day
euthanasia
mean
surviv
time
day
one
longterm
survivor
month
interferonv
group
hartmann
ritz
et
al
although
numer
studi
describ
treatment
cat
suspect
fip
review
demonstr
result
studi
interpret
caution
evalu
data
hamper
lack
wellcontrol
clinic
trial
new
treatment
compar
standard
care
placebo
studi
presenc
fip
confirm
treatment
initi
make
assess
outcom
imposs
also
evid
review
literatur
current
effect
therapeut
regim
control
fip
drug
effect
control
replic
fcov
vitro
like
ribavirin
unfortun
toxic
cat
vivo
start
antivir
treatment
time
point
clinic
sign
fip
alreadi
present
may
late
immunemedi
respons
viru
alreadi
overwhelm
treatment
cat
fip
remain
frustrat
success
limit
case
respond
favor
within
first
day
ill
none
declar
